Industrial Purity Specifications For (S)-1-(Tert-Butoxycarbonyl)-3-Hydroxypiperidine
- Critical Purity Thresholds: Pharmaceutical-grade batches require >98.0% purity via GC analysis with strict chiral excess controls.
- Downstream Impact: Impurity profiles directly affect Ibrutinib synthesis yields and final API regulatory compliance.
- Procurement Standards: Bulk orders must include comprehensive COA documentation covering residual solvents and heavy metals.
In the competitive landscape of pharmaceutical intermediate manufacturing, the quality of chiral building blocks dictates the success of downstream Active Pharmaceutical Ingredient (API) production. (S)-1-(tert-Butoxycarbonyl)-3-hydroxypiperidine, identified by CAS 143900-44-1, serves as a critical precursor in the synthesis of kinase inhibitors, most notably Ibrutinib. For process chemists and procurement managers, understanding the nuanced specifications beyond basic assay percentages is vital. As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. adheres to rigorous technical standards to ensure batch-to-batch consistency for large-scale production.
This technical overview details the essential purity criteria, analytical methods, and documentation required for securing high-quality bulk supplies of this piperidine derivative.
Standard Industrial Purity Criteria (GC/HPLC, KF, Residual Solvents)
When evaluating suppliers, the stated assay percentage is merely the starting point. True industrial purity encompasses chiral integrity, chemical impurities, and physical properties. For CAS 143900-44-1, the market standard for pharmaceutical intermediates typically demands a minimum assay of 98.0% determined by Gas Chromatography (GC). However, high-performance liquid chromatography (HPLC) is often employed alongside GC to detect non-volatile impurities that might skew results.
Chiral purity is arguably the most critical parameter. Since this molecule is used to introduce specific stereochemistry into complex drug molecules, the enantiomeric excess (ee) must be tightly controlled. Standard specifications often require an ee value of >99.0%. Any deviation can lead to diastereomeric impurities in the final API, complicating purification and potentially failing regulatory audits.
Furthermore, residual solvent analysis is mandatory. The manufacturing process often involves organic solvents such as methanol, ethanol, or ethyl acetate. According to ICH Q3C guidelines, these must be quantified to ensure they fall within permissible daily exposure limits. Water content, measured via Karl Fischer (KF) titration, should generally remain below 0.5% to prevent hydrolysis of the Boc protecting group during storage.
| Parameter | Specification Standard | Test Method |
|---|---|---|
| Assay (Purity) | >98.0% | GC / HPLC |
| Chiral Purity (ee) | >99.0% | Chiral HPLC / GC |
| Water Content | <0.5% | Karl Fischer Titration |
| Residual Solvents | Compliant with ICH Q3C | HeadSpace GC |
| Optical Rotation | [Ξ±]22/D +10.0Β° (c = 1 in CHCl3) |
Impact of Purity on Downstream API Synthesis
The utility of this compound lies primarily in its role as a key intermediate for Ibrutinib, a blockbuster therapy for B-cell malignancies. The synthesis route for Ibrutinib requires the precise coupling of this piperidine derivative with subsequent heterocyclic structures. If the starting material contains significant impurities, such as the (R)-enantiomer or over-reduced byproducts, these can carry through multiple synthetic steps.
Carryover impurities often necessitate additional recrystallization steps in later stages, drastically reducing overall yield and increasing production costs. In some cases, difficult-to-remove impurities can render a batch of API unusable. Therefore, sourcing high-purity materials is not just a quality control measure but an economic imperative. When sourcing high-purity (S)-1-Boc-3-hydroxypiperidine, buyers should prioritize suppliers who can demonstrate consistent chiral stability over time.
Biocatalytic reduction methods using recombinant keto reductases (KRED) have become the industry preference for generating this intermediate due to their ability to achieve >99% yield with exceptional stereoselectivity. Chemical reduction routes, while viable, often require more rigorous purification to meet the same chiral standards. Manufacturers utilizing biocatalysis can often offer better bulk price stability due to higher efficiency and lower waste disposal costs.
Certificate of Analysis (COA) Requirements for Bulk Shipments
For industrial-scale procurement, the Certificate of Analysis (COA) is the primary contractual document verifying quality. A robust COA for (S)-N-tert-Butoxycarbonyl-3-hydroxypiperidine must include specific batch data rather than typical ranges. Procurement teams should verify that the COA lists the specific lot number, manufacturing date, and retest date.
Key elements that must appear on a compliant COA include:
- Identity Confirmation: IR spectrum or NMR data matching the reference standard.
- Quantitative Assay: Clear indication of the method used (e.g., Area Normalization vs. External Standard).
- Impurity Profile: A chromatogram showing individual impurity peaks, ensuring no single unknown impurity exceeds 0.10%.
- Heavy Metals: Compliance with USP <231> or ICH Q3D guidelines.
NINGBO INNO PHARMCHEM CO.,LTD. ensures that every bulk shipment is accompanied by a full dossier including the COA, MSDS, and Method Validation Reports. This transparency is crucial for pharmaceutical companies filing Drug Master Files (DMF) with regulatory agencies.
Storage and Stability Considerations
Physical stability is another component of industrial specifications. The compound typically presents as a white to tan crystalline powder. It is hygroscopic and sensitive to light. Standard storage conditions require keeping the material in a dark place, sealed in dry containers at room temperature. Improper storage can lead to the degradation of the Boc group, resulting in the formation of the free amine, which complicates downstream reactions.
Long-term stability studies should be requested for bulk contracts. Generally, when stored correctly, the material maintains its specification for 24 months. However, once opened, immediate use or inert atmosphere storage is recommended to prevent moisture uptake.
Conclusion
Securing a reliable supply of CAS 143900-44-1 requires a partner who understands the intersection of synthetic chemistry and regulatory compliance. The difference between laboratory-grade and industrial-grade material lies in the consistency of chiral purity and the completeness of documentation. By prioritizing verified industrial purity and comprehensive COA data, manufacturers can safeguard their API production lines against costly delays.
For enterprises seeking a dependable supply chain for critical oncology intermediates, NINGBO INNO PHARMCHEM CO.,LTD. stands ready to provide technical support and scalable manufacturing solutions. Our commitment to quality ensures that your synthesis routes remain efficient and compliant with global pharmacopeial standards.